MedTrace Logo

Continuous Double Ovarian Stimulation.

NCT05815719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-18

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.

Conditions

  • Fertility Issues

Interventions

DRUG

Corifollitropin Alfa

150 micrograms per dose

DRUG

Follitropin Alfa

Variable dose.

DRUG

Follitropin Alfa Biosimilar

Variable dose.

DRUG

Urinary Human follicle stimulating hormone

Variable dose.

Sponsors & Collaborators

  • Instituto Bernabeu

    lead OTHER

Principal Investigators

  • Juan Carlos Castillo Farfan, MD, PhD · Instituto Bernabeu

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-17
Primary Completion
2023-04-30
Completion
2023-05-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815719 on ClinicalTrials.gov